These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17303388)

  • 21. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.
    Kluge M; Wehmeier PM; Dittmann RW; Langer F; Czekalla J; Lehmann M; Kessler FH; Beyenburg S; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):6-12. PubMed ID: 15706459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia.
    Aki H; Tomotake M; Kaneda Y; Iga J; Kinouchi S; Shibuya-Tayoshi S; Tayoshi SY; Motoki I; Moriguchi K; Sumitani S; Yamauchi K; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T
    Psychiatry Res; 2008 Feb; 158(1):19-25. PubMed ID: 18160137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH; Kim SY; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients.
    Balestrieri M; Giaroli G; Mazzi M; Bellantuono C
    Pharmacopsychiatry; 2006 May; 39(3):81-4. PubMed ID: 16721695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
    Schennach-Wolff R; Jäger M; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Seemüller F; Möller HJ; Riedel M
    World J Biol Psychiatry; 2010 Aug; 11(5):729-38. PubMed ID: 20380620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
    Kim EY; Chang SM; Shim JC; Joo EJ; Kim JJ; Kim YS; Ahn YM
    Curr Med Res Opin; 2013 Oct; 29(10):1231-40. PubMed ID: 23777311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
    Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
    Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
    Strous RD; Kupchik M; Roitman S; Schwartz S; Gonen N; Mester R; Weizman A; Spivak B
    Hum Psychopharmacol; 2006 Jun; 21(4):235-43. PubMed ID: 16783815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric evaluation of the Subjective Well-being Under Neuroleptic Treatment Scale (SWN) in patients with schizophrenia, their relatives and controls.
    Vothknecht S; Meijer C; Zwinderman A; Kikkert M; Dekker J; van Beveren N; Schoevers R; de Haan L;
    Psychiatry Res; 2013 Mar; 206(1):62-7. PubMed ID: 23021423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the Psychiatrist's Use of Subjective Well-Being Measurement in People with Schizophrenia Provide a Better Alignment with the Patient's Well-Being Perception than Clinical Judgement Alone?
    Aunjitsakul W; Teetharatkul T; Vitayanont A; Liabsuetrakul T
    Adm Policy Ment Health; 2021 Sep; 48(5):768-779. PubMed ID: 33728557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.
    Chen L; Phillips G; Johnston J; Kinon BJ; Ascher-Svanum H; Kollack-Walker S; Succop P; Naber D
    BMC Psychiatry; 2011 Dec; 11():203. PubMed ID: 22204569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012).
    Li Q; Xiang YT; Su YA; Shu L; Yu X; Correll CU; Ungvari GS; Chiu HF; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM; Kane JM
    Schizophr Res; 2015 Oct; 168(1-2):523-9. PubMed ID: 26277534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
    Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.
    Schmidt P; Clouth J; Haggenmüller L; Naber D; Reitberger U
    Qual Life Res; 2006 Sep; 15(7):1191-202. PubMed ID: 17004003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.
    Riedel M; Spellmann I; Schennach-Wolff R; Obermeier M; Musil R
    Qual Life Res; 2011 Mar; 20(2):263-72. PubMed ID: 20922485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.